Cargando…

Immunological network signatures of cancer progression and survival

BACKGROUND: The immune contribution to cancer progression is complex and difficult to characterize. For example in tumors, immune gene expression is detected from the combination of normal, tumor and immune cells in the tumor microenvironment. Profiling the immune component of tumors may facilitate...

Descripción completa

Detalles Bibliográficos
Autores principales: Clancy, Trevor, Pedicini, Marco, Castiglione, Filippo, Santoni, Daniele, Nygaard, Vegard, Lavelle, Timothy J, Benson, Mikael, Hovig, Eivind
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094196/
https://www.ncbi.nlm.nih.gov/pubmed/21453479
http://dx.doi.org/10.1186/1755-8794-4-28
_version_ 1782203514364100608
author Clancy, Trevor
Pedicini, Marco
Castiglione, Filippo
Santoni, Daniele
Nygaard, Vegard
Lavelle, Timothy J
Benson, Mikael
Hovig, Eivind
author_facet Clancy, Trevor
Pedicini, Marco
Castiglione, Filippo
Santoni, Daniele
Nygaard, Vegard
Lavelle, Timothy J
Benson, Mikael
Hovig, Eivind
author_sort Clancy, Trevor
collection PubMed
description BACKGROUND: The immune contribution to cancer progression is complex and difficult to characterize. For example in tumors, immune gene expression is detected from the combination of normal, tumor and immune cells in the tumor microenvironment. Profiling the immune component of tumors may facilitate the characterization of the poorly understood roles immunity plays in cancer progression. However, the current approaches to analyze the immune component of a tumor rely on incomplete identification of immune factors. METHODS: To facilitate a more comprehensive approach, we created a ranked immunological relevance score for all human genes, developed using a novel strategy that combines text mining and information theory. We used this score to assign an immunological grade to gene expression profiles, and thereby quantify the immunological component of tumors. This immunological relevance score was benchmarked against existing manually curated immune resources as well as high-throughput studies. To further characterize immunological relevance for genes, the relevance score was charted against both the human interactome and cancer information, forming an expanded interactome landscape of tumor immunity. We applied this approach to expression profiles in melanomas, thus identifying and grading their immunological components, followed by identification of their associated protein interactions. RESULTS: The power of this strategy was demonstrated by the observation of early activation of the adaptive immune response and the diversity of the immune component during melanoma progression. Furthermore, the genome-wide immunological relevance score classified melanoma patient groups, whose immunological grade correlated with clinical features, such as immune phenotypes and survival. CONCLUSIONS: The assignment of a ranked immunological relevance score to all human genes extends the content of existing immune gene resources and enriches our understanding of immune involvement in complex biological networks. The application of this approach to tumor immunity represents an automated systems strategy that quantifies the immunological component in complex disease. In so doing, it stratifies patients according to their immune profiles, which may lead to effective computational prognostic and clinical guides.
format Text
id pubmed-3094196
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30941962011-05-14 Immunological network signatures of cancer progression and survival Clancy, Trevor Pedicini, Marco Castiglione, Filippo Santoni, Daniele Nygaard, Vegard Lavelle, Timothy J Benson, Mikael Hovig, Eivind BMC Med Genomics Research Article BACKGROUND: The immune contribution to cancer progression is complex and difficult to characterize. For example in tumors, immune gene expression is detected from the combination of normal, tumor and immune cells in the tumor microenvironment. Profiling the immune component of tumors may facilitate the characterization of the poorly understood roles immunity plays in cancer progression. However, the current approaches to analyze the immune component of a tumor rely on incomplete identification of immune factors. METHODS: To facilitate a more comprehensive approach, we created a ranked immunological relevance score for all human genes, developed using a novel strategy that combines text mining and information theory. We used this score to assign an immunological grade to gene expression profiles, and thereby quantify the immunological component of tumors. This immunological relevance score was benchmarked against existing manually curated immune resources as well as high-throughput studies. To further characterize immunological relevance for genes, the relevance score was charted against both the human interactome and cancer information, forming an expanded interactome landscape of tumor immunity. We applied this approach to expression profiles in melanomas, thus identifying and grading their immunological components, followed by identification of their associated protein interactions. RESULTS: The power of this strategy was demonstrated by the observation of early activation of the adaptive immune response and the diversity of the immune component during melanoma progression. Furthermore, the genome-wide immunological relevance score classified melanoma patient groups, whose immunological grade correlated with clinical features, such as immune phenotypes and survival. CONCLUSIONS: The assignment of a ranked immunological relevance score to all human genes extends the content of existing immune gene resources and enriches our understanding of immune involvement in complex biological networks. The application of this approach to tumor immunity represents an automated systems strategy that quantifies the immunological component in complex disease. In so doing, it stratifies patients according to their immune profiles, which may lead to effective computational prognostic and clinical guides. BioMed Central 2011-03-31 /pmc/articles/PMC3094196/ /pubmed/21453479 http://dx.doi.org/10.1186/1755-8794-4-28 Text en Copyright ©2011 Clancy et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Clancy, Trevor
Pedicini, Marco
Castiglione, Filippo
Santoni, Daniele
Nygaard, Vegard
Lavelle, Timothy J
Benson, Mikael
Hovig, Eivind
Immunological network signatures of cancer progression and survival
title Immunological network signatures of cancer progression and survival
title_full Immunological network signatures of cancer progression and survival
title_fullStr Immunological network signatures of cancer progression and survival
title_full_unstemmed Immunological network signatures of cancer progression and survival
title_short Immunological network signatures of cancer progression and survival
title_sort immunological network signatures of cancer progression and survival
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094196/
https://www.ncbi.nlm.nih.gov/pubmed/21453479
http://dx.doi.org/10.1186/1755-8794-4-28
work_keys_str_mv AT clancytrevor immunologicalnetworksignaturesofcancerprogressionandsurvival
AT pedicinimarco immunologicalnetworksignaturesofcancerprogressionandsurvival
AT castiglionefilippo immunologicalnetworksignaturesofcancerprogressionandsurvival
AT santonidaniele immunologicalnetworksignaturesofcancerprogressionandsurvival
AT nygaardvegard immunologicalnetworksignaturesofcancerprogressionandsurvival
AT lavelletimothyj immunologicalnetworksignaturesofcancerprogressionandsurvival
AT bensonmikael immunologicalnetworksignaturesofcancerprogressionandsurvival
AT hovigeivind immunologicalnetworksignaturesofcancerprogressionandsurvival